[Efficacy and safety of domestic and brand name bortezomib in the treatment of newly diagnosed multiple myeloma].

Sun, H M; Jiang, Z X; Wang, W M; Wang, S J; Ge, F F; Li, J D; Zhao, H M

Sun, H M; Jiang, Z X; Wang, W M; Wang, S J; Ge, F F; Li, J D; Zhao, H M.

Afiliação

Sun HM; Henan Provincial People's Hospital, International Medical Center of Henan, People's Hospital of Zhengzhou University, People's Hospital of Henan University, Zhengzhou 450000, China.
Jiang ZX; Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China.
Wang WM; Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China.
Wang SJ; Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China.
Ge FF; Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China.
Li JD; Department of Hematology, The First Affiliated Hospital of Xinxiang Medical College, Weihui 453100, China.
Zhao HM; Department of Hematology, Huaihe Hospital of Henan University, Kaifeng 475000, China.

Zhonghua Xue Ye Xue Za Zhi ; 41(3): 261-263, 2020 03 14.

Article em Zh | MEDLINE | ID: mdl-32311900

Assuntos

Bortezomib/uso terapêutico; Mieloma Múltiplo; Protocolos de Quimioterapia Combinada Antineoplásica; Dexametasona; Humanos; Mieloma Múltiplo/tratamento farmacológico; Resultado do Tratamento

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Bortezomib / Mieloma Múltiplo Tipo de estudo: Diagnostic_studies Limite: Humans Idioma: Zh Revista: Zhonghua Xue Ye Xue Za Zhi Ano de publicação: 2020 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google